MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574875 | Name: SD-1008
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SD-1008 is an inhibitor of the JAK2/STAT3 signaling pathway. SD-1008 induces apoptosis in cell lines expressing constitutively active tyrosine-phosphorylated STAT3

Chemical Structure

SD-1008
SD-1008
CAS#960201-81-4

Theoretical Analysis

MedKoo Cat#: 574875

Name: SD-1008

CAS#: 960201-81-4

Chemical Formula: C18H19NO5

Exact Mass: 329.1263

Molecular Weight: 329.35

Elemental Analysis: C, 65.64; H, 5.82; N, 4.25; O, 24.29

Price and Availability

Size Price Availability Quantity
10mg USD 600.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SD 1008; SD1008; SD-1008
IUPAC/Chemical Name
(1R,5R,6S,7R)-dimethyl 8-benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6,7-dicarboxylate
InChi Key
PYZQFEIRZQYUJQ-MIGQKNRLSA-N
InChi Code
InChI=1S/C18H19NO5/c1-23-17(21)14-12-8-9-13(20)16(15(14)18(22)24-2)19(12)10-11-6-4-3-5-7-11/h3-9,12,14-16H,10H2,1-2H3/t12-,14-,15-,16+/m1/s1
SMILES Code
O=C([C@H]1[C@@H]2C(C=C[C@@H](N2CC3=CC=CC=C3)[C@H]1C(OC)=O)=O)OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway.
In vitro activity:
SD-1008 is a promising therapeutic agent for cancer treatment. In this study, SD-1008 was identified as a micromolar inhibitor of interleukin-6 or oncostatin-induced signal transducer and activator of STAT3 nuclear translocation. SD-1008 also targeted the upstream components of the STAT3 pathway. Exposure to SD-1008 induced apoptosis in various cell lines by decreasing levels of STAT3-dependent protein; SD-1008 enhanced the apoptotic effect of paclitaxel in ovarian cancer cells. Reference: Mol Pharmacol. 2007 Nov;72(5):1137-45. https://pubmed.ncbi.nlm.nih.gov/17675586/
In vivo activity:
To be determined

Preparing Stock Solutions

The following data is based on the product molecular weight 329.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Liu Z, Gan L, Zhou Z, Jin W, Sun C. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte. Immunobiology. 2015 Aug;220(8):947-53. doi: 10.1016/j.imbio.2015.02.004. Epub 2015 Feb 14. PMID: 25720636. 2. Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007 Nov;72(5):1137-45. doi: 10.1124/mol.107.038117. Epub 2007 Aug 3. PMID: 17675586.
In vitro protocol:
1. Liu Z, Gan L, Zhou Z, Jin W, Sun C. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte. Immunobiology. 2015 Aug;220(8):947-53. doi: 10.1016/j.imbio.2015.02.004. Epub 2015 Feb 14. PMID: 25720636. 2. Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007 Nov;72(5):1137-45. doi: 10.1124/mol.107.038117. Epub 2007 Aug 3. PMID: 17675586.
In vivo protocol:
To be determined
1. Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007 Nov;72(5):1137-45. doi: 10.1124/mol.107.038117. Epub 2007 Aug 3. PMID: 17675586.